Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, commercial and real world insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share diverse insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health is powered by an authentic, inclusive and high-performance culture that cares for colleagues, customers, patients, communities and the environment.
Unlock the market timeline & signal feed
New Marketing & PR activity — 17 fresh signals just appeared.
The order this company entered each market — oldest to newest
104 active postings
35 active postings
Sign up to see the full signal feed
How Syneos Health's international expansion compares to its competitors
Syneos HealthYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Syneos HealthYou | 35 | 1 | +33% | 147 | 35 |
CRA - I/II
View postingBeijing, Beijing, China · yesterday
Site Activation Manager assigned to Client
View postingMexico City Metropolitan Area · yesterday
Payment Specialist I (Finance CTA) - Istanbul Based - Hybrid
View postingIstanbul, Türkiye · yesterday
What signals emerged from ASCO 2026?Recorded live from the Syneos Health Early Signals podcast booth, leaders and innovators across biopharma, academia and technology shared perspectives on the trends shaping the future of oncology.From AI and precision medicine to cell therapy and real-world evidence, explore the key insights and emerging signals that could help define what's next for patients.Read the full ASCO 2026 conference capsule. ...
EndedIncretins. CKM therapies. Combination treatments. Cardiometabolic innovation is advancing rapidly—but complexity is growing just as fast.Discover how our cross-therapeutic model helps sponsors accelerate development in cardiovascular, metabolic and renal programs with greater clarity and speed to market. ...
Ended
The future of cardiometabolic drug development depends on seeing the full picture.Risk doesn't develop in silos and neither should our development strategies.As we head into ADA 2026, I share perspectives on why approaching cardiometabolic disease as an interconnected continuum may help reshape how we think about trial design, risk management and long-term patient outcomes.Read more: Rethinking Risk, Improving Outcomes in Cardiometabolic Drug Development https://lnkd.in/ePUtrRs3If you will be at ...
EndedVeeva Systems' Vault EDC has supported over 1000 trials, with 8 of top 20 biopharma firms standardizing on it, improving clinical data management efficiency.
Telix Pharmaceuticals appoints David Gill as Non-Executive Director effective May 11, 2026, with plans for him to become Chair. Gill brings 35+ years of life sciences experience.
Crossject partners with Syneos Health for US commercial launch of ZEPIZURE, an emergency epilepsy treatment using needle-free auto-injector technology.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Syneos Health's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
